Last reviewed · How we verify

Abelcet — Competitive Intelligence Brief

Abelcet (AMPHOTERICIN B) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipid-based Polyene Antifungal [EPC]. Area: Immunology.

marketed Lipid-based Polyene Antifungal [EPC] Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Abelcet (AMPHOTERICIN B) — Astellas Pharma.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Abelcet TARGET AMPHOTERICIN B Astellas Pharma marketed Lipid-based Polyene Antifungal [EPC] 1964-01-01
Amphotericin B Liposome Amphotericin B Liposome Aurobindo Pharma Ltd marketed Lipid-based Polyene Antifungal [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipid-based Polyene Antifungal [EPC] class)

  1. Astellas Pharma · 1 drug in this class
  2. Aurobindo Pharma Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abelcet — Competitive Intelligence Brief. https://druglandscape.com/ci/amphotericin-b. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: